Skip to main content

Table 1 Baseline characteristics of the patient population (N = 44)

From: Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Characteristic Total (N = 44)
Age, years  
 Median 67
 Range 51–84
Gleason score available, n (%) 39 (89)
 ≤7 15 (38)
 >7 24 (62)
PSA level at baseline, ng/mL  
 Median 22.2
 Range 0.2–746
Extent of disease, n (%)  
 Local relapse 6 (14)
 Locoregional 1 (2)
 Metastases total 36 (84)
 Peritoneum 1 (2)
 Pelvis 1 (2)
 Bladder 1 (2)
 Lung 3 (7)
 Liver 1 (2)
 Lymph nodes 26 (59)
 Bone 28 (64)
ECOG, n (%)  
 0 43 (98)
 1 1 (2)
Time since diagnosis, weeks  
 Mean 280.4
 SD 228.15
Previous therapy, n (%)  
 Prostatectomy 23 (52)
 Radiotherapy 28 (64)
 Hormone ablation 44 (100)
  1. ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; SD, standard deviation